Claims

Search Type State Status Topic Model Order Counting Over

As of snapshot 27745 under ledger-default@0.3.0.

Claim	Type	Assessment	Score	Review checks	References
In a retrospective metastatic prostate-cancer cohort, among cases classified as IMF6-high, androgen-receptor pathway inhibitor treatment was associated with lower treatment-failure risk than taxane treatment (HR 0.21, 95% CI 0.05–0.79, P = 0.021).	QUANTITATIVE	Supported	0.8808	1 of 4	120
In a study of 959 primary prostate-cancer donors, eight integrated mutational footprints collectively explained the mutational processes in 85% of primary prostate-cancer genomes; four footprints present in 37% of primary tumours were associated with shorter time to metastasis.	QUANTITATIVE	Supported	0.9781	1 of 4	105